Herantis Pharma releases 2H and FY 2025 report today

Core Viewpoint - Herantis Pharma has made significant progress in 2025, particularly with the positive topline data from the Phase 1b trial of HER-096 for Parkinson's disease, confirming its safety, tolerability, and ability to cross the blood-brain barrier [2][6][14]. Financial Performance - For the full year 2025, Herantis reported a loss of EUR 6.62 million, compared to a loss of EUR 4.94 million in 2024 [12]. - Operating income decreased to EUR 178 thousand in 2025 from EUR 1.56 million in 2024 [12]. - Payroll and related expenses increased to EUR 1.92 million in 2025 from EUR 1.49 million in 2024 [12]. - The equity ratio remained negative at -0.63 for both 2025 and 2024 [12]. Clinical Development - The Phase 1b trial of HER-096 met all primary and secondary endpoints, demonstrating safety and tolerability with both 200 mg and 300 mg doses [6][14]. - Biomarker data from the trial indicated a biological response to HER-096, showing modulation of key disease-related pathways, which supports further clinical development [10][14]. - A six-month preclinical GLP toxicology study for HER-096 showed a favorable safety profile, aligning with previous data [8][14]. Funding and Financial Strategy - Herantis secured a non-dilutive grant of EUR 8 million from Horizon Europe to support the Phase 2 trial [4][11]. - The company completed a directed share issue raising EUR 4.2 million, enhancing its financial flexibility [4][11]. - A previous directed share issue raised EUR 5.2 million in February 2025 [5]. Future Outlook - The company is preparing for a Phase 2 proof-of-concept trial of HER-096, with study design plans underway and targeting initiation after current preparations [15]. - The biomarker data will be presented at scientific conferences and submitted for publication, aiding in dose selection and clinical endpoint refinement [14].